Vascular cognitive impairment

Lancet Neurology

Volumn 2, Issue 2, 2003, Pages 89-98

  O'Brien, John T ^a   Erkinjuntti, Timo ^b   Reisberg, Barry ^c   Roman, Gustavo ^d   Sawada, Tohru ^d,e   Pantoni, Leonardo ^f   Bowler, John V ^g   Ballard, Clive ^a   DeCarli, Charles ^h   Gorelick, Philip B ⁱ   Rockwood, Kenneth ^j   Burns, Alistair ^k   Gauthier, Serge ^l   DeKosky, Steven T ^m  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^f UNIVERSITY OF FLORENCE   (Italy)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ RUSH MEDICAL COLLEGE   (United States)

^j DALHOUSIE UNIVERSITY   (Canada)

^k WYTHENSHAWE HOSPITAL   (United Kingdom)

^l MCGILL UNIVERSITY   (Canada)

^m UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CALCIUM ANTAGONIST; CHOLINESTERASE INHIBITOR; DONEPEZIL; FIBRINOLYTIC AGENT; GALANTAMINE; MEMANTINE; NEUROPROTECTIVE AGENT; NIMODIPINE; NOOTROPIC AGENT; PROPENTOFYLLINE; VASODILATOR AGENT; WARFARIN;

ALZHEIMER DISEASE; APATHY; ATTENTION; BRAIN CORTEX; BRAIN ISCHEMIA; BRAIN REGION; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; GENETIC DISORDER; HEALTH CARE; HUMAN; IMAGE ANALYSIS; MEMORY; MENTAL DISEASE; MULTIINFARCT DEMENTIA; PATHOPHYSIOLOGY; PATIENT CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCIENCE; SECONDARY PREVENTION; STROKE; TREATMENT INDICATION; VALIDATION PROCESS; VASCULAR COGNITIVE IMPAIRMENT; VASCULAR DISEASE; WHITE MATTER; CEREBROVASCULAR DISEASE; CLASSIFICATION; GENETICS; NOMENCLATURE;

CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; TERMINOLOGY;

EID: 0038049262     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00305-3     Document Type: Review

References (107)

1. Hofman A., Rocca W.A., Brayne C. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings - Eurodem Prevalence Research Group. Intern J Epidemiol. 20:1991;736-748.
2. Lobo A., Launer L.J., Fratiglioni L. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts - Neurologic Diseases in the Elderly Research Group. Neurology. 54:(suppl):2000;4-9.
3. Robertson D., Rockwood K., Stolee P. The prevalence of cognitive impairment in an elderly Canadian population. Acta Psychiatr Scand. 80:1989;303-309.
4. Rocca W.A., Hofman A., Brayne C. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings: the EURODEM-Prevalence Research Group. Ann Neurol. 30:1991;381-390.
5. White L., Petrovitch H., Ross G.W. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging study. JAMA. 276:1996;955-960.
6. Ritchie K., Artero S., Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 56:2001;37-42.
7. Schroder J., Kratz B., Pantel J., Minnemann E., Lehr U., Sauer H., et al. Prevalence of mild cognitive impairment in an elderly community sample. J Neural Transm Suppl. 54:1998;51-59.
8. Melzer D., Ely M., Brayne C. Cognitive impairment in elderly people: population based estimate of the future in England, Scotland, and Wales. BMJ. 315:1997;462.
9. Di Carlo A., Launer L.J., Breteler M.M., et al. Frequency of stroke in Europe: a collaborative study of population-based cohorts - ILSA Working Group and the Neurologic Diseases in the Elderly Research Group: Italian Longitudinal Study on Aging. Neurology. 54:(11 suppl 5):2000;S28-S33.
10. Pohjasvaara T., Erkinjuntti T., Ylikoski R., et al. Clinical determinants of poststroke dementia. Stroke. 29:1998;75-81.
11. O'Brien J., Ballard C. Drugs for Alzheimer's disease. BMJ. 323:2001;123-124.
12. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfield S., Damaraju C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 359:2002;1283-1290.
13. Hachinski V.C., Lassen N.A., Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet. 2:1974;207-210.
14. Ballard C., McKeith I., O'Brien J. Neuropathological substrates of dementia and depression in vascular dementia, with a particular focus on cases with small infarct volumes. Dement Geriatr Cogn Disord. 11:2000;59-65.
15. Erkinjuntti T., Bowler J.V., DeCarli C.S. Imaging of static brain lesions in vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord. 13:(suppl):1999;81-90.
16. Esiri M.M., Wilcock G.K., Morris J.H. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry. 63:1997;749-753.
17. Pohjasvaara T., Mantyla R., Ylikoski R., Kaste M., Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia: National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et I'Enseignement en Neurosciences. Stroke. 31:2000;2952-2957.
18. Rockwood K., Bowler J., Erkinjuntti T., Hachinski V., Wallin A. Subtypes of vascular dementia. Alzheimer Dis Assoc Disord. 13:(suppl 3):1999;59-65.
19. Roman G.C., Tatemichi T.K., Erkinjuntti T. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 43:1993;250-260.
20. Skoog I., Lernfelt B., Landahl S. 15-year longitudinal study of blood pressure and dementia. Lancet. 347:1996;1141-1145.
21. Launer L.J., Ross G.W., Petrovik H., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 21:2000;49-55.
22. Ott A., Stolk R.P., van Harskamp F., et al. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 53:1999;1937-1942.
23. Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabetes Med. 16:1999;93-112.
24. Ott A., Slooter A.J., Hofman A., et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam study. Lancet. 351:1998;1840-1843.
25. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 356:2000;1627-1631.
26. Rockwood K., Kirkland S., Hogan D.B. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 59:2002;223-227.
27. Snowdon D.A., Greiner L.H., Mortimer J.A., et al. Brain infarction and the clinical expression of Alzheimer disease: the Nun study. JAMA. 277:1997;813-817.
28. Hachinski V., Lassen N., Marshall J. When vascular disease is responsible for dementia it is through the occurrence of multiple small or large cerebral infarcts. Lancet. 2:1974;207-219.
29. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 357:2001;169-175.
30. Esiri M.M., Nagy Z., Smith M.Z., Barnetson L., Smith A.D. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 354:1999;919-920.
31. Roman G.C. Senile dementia of the Binswanger type: a vascular form of dementia in the elderly. JAMA. 258:1987;1782-1788.
32. Babikian V., Ropper A.H. Binswanger's disease: a review. Stroke. 18:1987;2-12.
33. Ishii N., Nishihara Y., Imamura T. Why do frontal lobe symptoms predominate in vascular dementia with lacunes? Neurology. 36:1986;340-345.
34. Erkinjuntti T., Inzitari D., Pantoni L. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 59:2000;23-30.
35. Ross G.W., Petrovitch H., White L.R. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology. 53:1999;337-343.
36. Masaki K.H., Losonczy K.G., Izmirlian G. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 54:2000;1265-1272.
37. Breteler M.M.B., van Swieten J.C., Bots M.L. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam study. Neurology. 44:1994;1246-1252.
38. De Groot J.C., de Leeuw F.E., Oudkerk M., et al. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam scan study. Neurology. 56:2001;1539-1545.
39. Ylikoski R., Ylikoski A., Erkinjuntti T., et al. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol. 50:1993;818-824.
40. O'Brien J., Perry R., Barber R., Gholkar A., Thomas A. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann NY Acad Sci. 903:2000;482-489.
41. Barber R., Gholkar A., Ballard C., et al. White matter lesions on MRI in dementia with Lewy bodies, Alzheimer's disease, vascular dementia and normal ageing. J Neurol Neurosurg Psychiatry. 67:1999;66-72.
42. Meyer J.S., Raunch G.M., Crawford K., et al. Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry. 14:1999;1050-1061.
43. Premkumar D.R.D., Cohen D.L., Hedera P., Friedland R.P., Kalaria R.N. Apolipoprotein E e4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology in Alzheimer's disease. Am J Pathol. 148:1996;2083-2095.
44. Natte R., Maat-Schieman L.C., Haan J., Bornebroek, Roos R.A.C., van Duinen G. Dementia in hereditary cerebral hemorrhage with amyloidosis: Dutch type is associated with cerebral amyloid angiopathy, but is independent of plaques and neurofibrillary tangles. Ann Neurol. 50:2001;762-765.
45. Hofman A., Ott A., Breteler M.M.B., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet. 349:1997;151-154.
46. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 346:2002;476-483.
47. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association, 1994.
48. th edn. Geneva: WHO, 1992.
49. Chui H.C., Victoroff J.I., Margolin D., Jagust W., Shankle R., Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 42:1992;473-480.
50. Roman G.C., Tatemichi T.K., Erkinjuntti T. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN international workshop. Neurology. 43:1993;250-260.
51. Wetterling T., Kanitz R.D., Borgis K.J. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV-ICD-10, NINDS-AIREN). Stroke. 27:1996;30-36.
52. Chui H.C., Mack W., Jackson J.E. Clinical criteria for the diagnosis of vascular dementia: a multi-centre study of comparability and inter-rater reliability. Arch Neurol. 57:2000;191-196.
53. Pohjasvaara T., Mantyla R., Salonen O. How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol. 57:2000;1295-1300.
54. Gold G., Bouras C., Canuto A. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry. 159:2002;82-87.
55. Mori E., Ishii K., Hashimoto M., et al. Role of functional brain imaging in the evaluation of vascular dementia. Alzheimer Dis Assoc Disord. 13:(suppl 3):1999;91-101.
56. O'Donnell H.C., Rosand J., Knudsen K.A., et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 342:2000;240-245.
57. Dichgans M., Joutel A. Cerebrovascular disorders. Rimoin D., Connor J.M., Pyeritz R.E., Korf B. Emery and Rimoin's principles and practice of medical genetics. 2002;3209-3230 Churchill Livingstone, London.
58. Dichgans M., Mayer M., Uttner I., et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 44:1998;731-739.
59. Aurer D.P., Putz B., Gossl C., Elbel G.K., Gasser T., Dichgans M. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology. 218:2001;443-451.
60. Joutel A., Andreux F., Gaulis S., et al. The ectodomain of Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 105:2000;597-605.
61. Garcia J.H., Brown C.G. Vascular dementia: neuropathologic alterations and metabolic brain changes. J Neurol Sci. 109:1992;121-131.
62. Munoz D.G. The pathological basis of multi-infarct dementia. Alzheimer Dis Assoc Disord. 5:1991;77-90.
63. Olsson Y., Brun A., Englund E. Fundamental pathological lesions in vascular dementia. Acta Neurol Scand. 168:1996;31-38.
64. Pantoni L., Lammie A. Cerebral small vessel disease: pathological and pathophysiological aspects in relation to vascular cognitive impairment. Erkinjunti T., Gauthier S. Vascular cognitive impairment. 2002;1115-1134 Martin Dunitz, London.
65. Inzitari D., Erkinjuntti T., Wallin A., del Ser T., Romanelli M., Pantoni L. Subcortical vacular dementia as a specific target for clinical trials. Ann NY Acad Sci. 903:2000;510-521.
66. Brun A. Pathology and pathophysiology of cerebrovascular dementia: pure subgroups of obstructive and hypoperfusive etiology. Dementia. 5:1994;145-147.
67. Chui H.C. Vascular dementia, a new beginning: shifting focus from clinical phenotype to ischemic brain injury. Neurol Clin. 18:2001;951-977.
68. Cummings J.L. Fronto-subcortical circuits and human behavior. Arch Neurol. 50:1993;873-880.
69. Kapeller P., Ropele S., Fazekas F. White matter imaging: technical considerations including histopathological correlation. Pantoni L., Inzitari D., Wallin A. The matter of white matter: clinical and pathophysiological aspects of white matter disease related to cognitive decline and vascular dementia. 2000;123-139 Academic Pharmaceutical Productions, Utrecht.
70. Erkinjuntti T., Inzitari D., Pantoni L., et al. Limitations of clinical criteria for the diagnosis of vascular dementia in clinical trials. Is a focus on subcortical vascular dementia a solution? Ann NY Acad Sci. 903:2000;262-272.
71. Vataja R., Pohjasvaara T., Leppävuori A., et al. Magnetic resonance imaging correlates of depression after ischemic stroke. Arch Gen Psychiatry. 58:2001;925-931.
72. Chui H., Gonthier R. Natural history of vascular dementia. Alzheimer Dis Assoc Disord. 13:(suppl 3):1999;124-130.
73. Kittner B., DeDeyn P.P., Erkinjuntti T. Investigating the natural course of vascular dementia and Alzheimer's disease: parallel study populations in two randomized, placebo-controlled trials. Ann NY Acad Sci. 903:2000;535-541.
74. Wentzel C., Rockwood K., MacKnight C., et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology. 57:2001;714-716.
75. Varpetian A., Gonthier R., Chui H. Natural history of vascular dementia. Erkinjuntti T., Gauthier S. Vascular cognitive impairment. 2002;541-556 Martin Dunitz, London.
76. Wolf H., Ecke G.M., Bettin S., Dietrich J., Gertz H.J. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? a longitudinal study. Int J Geriatr Psychiatry. 15:2000;803-812.
77. Schmidt R., Fazakas F., Kapeller P., Schmidt H., Hartung H.P. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology. 53:1999;132-139.
78. Veldink J., Scheltens P., Jonker C. Progression of cerebral white matter hyperdensities on MRI is related to diastolic blood pressure. Neurology. 51:1998;319-320.
79. Mungas D., Reed B.R., Ellis W.G., Jagust W.J. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol. 58:2001;1243-1247.
80. Wardlaw J. Overview of Cochrane thrombolysis meta-analysis. Neurology. 57:2001;S69-S76.
81. Gorelick P.B. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls? Lancet. 355:2000;1925-1926.
82. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischaemic stroke pathogenesis and implications for therapy. Stroke. 33:2002;862-875.
83. Erkinjuntii T., Rockwood K. Vascular cognitive impairment. Psychogeriatrics. 1:2001;27-38.
84. Kittner B., Rossner M., Rother M. Clinical trials in dementia with propentofylline. Ann NY Acad Sci. 826:1997;307-316.
85. Orgogozo J-M, Rigaud A-S, Stöffler A, Möbius H-J, Forette F. Efficacy and safety of Mementaine in patients with mild to moderate vascular dementia: a randomised, placebo-controlled trial (MMM 300). Stroke (in press).
86. Lopez-Arrieta BJ. Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). Cochrane Database Syst Rev 2001;1:CD000147.
87. Pantoni L., Bianchi C., Beneke M., Inzitari D., Wallin A., Erkinjuntti T. The Scandinavian multi-infarct dementia trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 175:2000;116-123.
88. Pantoni L., Rossi R., Inzitari D., et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian multi-infarct dementia trial. J Neurol Sci. 175:2000;124-134.
89. Pratt RD, Perdomo CA, The Donepezil 308 VaD Study Group. Cognitive and global benefits of donepezil in vascular dementia: results from study 308, a 24-week, randomized, double-blind, placebo-controlled trial. 2nd International Congress on Vascular Dementia, January 25-27, 2002, Salzburg, Austria (abstr).
90. Li Y.S., Meyer J.S., Haque A., Chowdhury M., Hinh P., Quach M. Feasibility of vascular dementia treatment with cholinesterase inhibitors. Int J Geriatr Psychiatry. 17:2002;193-196.
91. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju C.V. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet. 329:2002;1283-1290.
92. Barber R., Gholkar A., Ballard C., Scheltens P., McKeith I., O'Brien J.T. Temporal lobe atrophy on MRI in dementia with Lewy bodies: a comparison with Alzheimer's disease, vascular dementia and normal ageing. Neurology. 52:2000;1153-1158.
93. Mohs R.C., Knopman D., Petersen R.C., et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope - the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 11:(suppl 2):1997;S13-S21.
94. Ferris S., Gauthier S. Cognitive outcome measures in vascular dementia. Erkinjuntti T., Gauthier S. Vascular cognitive impairment. 2002;541-555 Martin Dunitz, London.
95. Gelinas I., Gauthier L. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 53:1999;471-481.
96. Gauthier S., Gègelinas. Evaluation of daily activities in vascular cognitive impairment. Erkinjuntti T., Gauthier S. Vascular cognitive impairment. 2002;411-416 Martin Dunitz, London.
97. Reisberg B., Ferris S., Oo T., Fransen E. Staging: relevance for trial design in vascular burden of the brain. Erkinjuntti T., Gauthier S. Vascular cognitive impairment. 2002;557-569 Martin Dunitz, London.
98. Reisberg B., Borenstein J., Salob S.P., Ferris S.H., Franssen E., Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 48:(suppl):1987;9-15.
99. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 44:1994;2308-2314.
100. Mittelman M., Ferris S., Steinberg G., et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. Gerontologist. 33:1993;730-740.
101. Mittelman M., Ferris S., Shulman E., et al. A comprehensive support program: effect on depression in spouse-caregivers of AD patients. Gerontologist. 35:1995;792-802.
102. Mittelman M.S., Ferris S.H., Shulman E., Steinberg G., Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease. JAMA. 276:1996;1725-1731.
103. Ferris S.H., Mittelman M.S. Behavioral treatment of Alzheimer's disease. Int Psychogeriatrics. 8:(suppl 1):1996;87-90.
104. Mittelman M.S., Ferris S.H., Shulman E., et al. The effects of a multicomponent support program on spouse-caregivers of Alzheimer's disease patients: results of a treatment/control study. Heston L.L. Progress in Alzheimer's disease and similar conditions. 1997;American Psychiatric Press, Washington, DC.
105. Tarrier N, Ward J, Burns A, Donaldson C, Barrowclough C. Expressed emotion and attributes in the carers of patients with Alzheimer's disease: the effect on carer burden. J Abnorm Psychol (in press).
106. Burns A., Russell E., Stratton-Powell H., et al. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry. 14:1999;681-685.
107. Wimo A., Jönsson L., Winblad B. Societal burden and pharmacoeconomics of vascular dementia. Erkinjuntti T., Gauthier S. Vascular cognitive impairment. 2002;629-639 Martin Dunitz, London.